@article{3340571,
    title = "An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options",
    author = "Church, M.K. and Canonica, G.W. and Kuna, P. and Maurer, M. and Mösges, R. and Novak, Z. and Papadopoulos, N.G. and Rodriguez del Rio, P. and the Delphi Study Group",
    journal = "Expert Review of Clinical Immunology",
    year = "2023",
    publisher = "Taylor and Francis Ltd.",
    issn = "1744-666X, 1744-8409",
    doi = "10.1080/1744666X.2023.2214729",
    abstract = "Background: Allergic rhinoconjunctivitis and chronic urticaria are common histamine-driven diseases, exerting detrimental effects on cognitive functions, sleep, daily activities, and quality of life. Non-sedating second-generation H1-antihistamines are the first-line treatment of choice. Aim of the study was to define the role of bilastine among second-generation H1-antihistamines in the treatment of allergic rhinoconjunctivitis and urticaria in patients of different ages. Methods: An international Delphi study was carried out to assess consensus among experts from 17 European and extra-European countries on three main topics: 1) Burden of disease; 2) Current treatment options; 3) Specific characteristics of bilastine among second-generation antihistamines. Results: Here, we present the results obtained for a selection of 15 out of 27 consensus statements, focused on disease burden, role of second-generation antihistamines and bilastine profile. The rate of concordance was ≥98% for 4 statements, ≥ 96% for 6, ≥ 94% for 3, and ≥90% for 2. Conclusions: The high degree of agreement obtained suggests a wide awareness of the burden of allergic rhinoconjunctivitis and chronic urticaria among experts from all over the world and reflects a broad consensus on the role of second-generation antihistamines in general and of bilastine in particular for their management. © 2023 Informa UK Limited, trading as Taylor & Francis Group."
}